Syros Pharmaceuticals, Inc. significantly extended its financial runway through three concurrent transactions on 5 July that are expected to fund company operations into 2025 and get it well past the expected readout of pivotal Phase III data for its lead candidate tamibarotene in higher-risk myelodysplastic syndrome (HR-MDS) patients. In the process, Syros will merge with Tyme Technologies, Inc., acquiring about $60m in cash and that company’s stalled cancer metabolism-based therapy SM-88.
Syros Gets ‘Tyme’ To Bring Lead Candidate To Pivotal Readout
Gene-expression focused Syros adds about $190m to its coffers with Tyme merger and PIPE financing. This will get it past pivotal data for tamibarotene and enable Phase III development of a leukemia candidate.
More from Deals
More from Business
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.